AtriCure (ATRC) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $100M

Market Cap: $1.4BFounded: 2000Employees: 1000-5000HQ: Mason, Netherlands

Overview

AtriCure is a publicly traded medical device company focused on developing and commercializing technologies for the interventional treatment of atrial fibrillation and post-operative pain management. The company has established itself through three synergistic platforms: Surgical Ablation, Left Atrial Appendage (LAA) Management, and Cryoanalgesia. Its strategy involves expanding the use of its therapies in both cardiac and non-cardiac surgical settings, supported by a robust clinical evidence program and a global direct sales force. Recent achievements include the launch of new products like the cryoXT probe and the initiation of the pivotal BoxX-NoAF trial to expand its addressable patient population.

CardiovascularPain Management

Technology Platform

Three synergistic platforms: 1) Surgical Ablation (RF & Cryo) for atrial fibrillation, 2) Left Atrial Appendage (LAA) Management for stroke prevention, and 3) Cryo Nerve Block (Cryoanalgesia) for non-opioid post-operative pain control.

Funding History

2

Total raised:$100M

Debt$100MUndisclosedMar 15, 2021

IPOUndisclosedUndisclosedAug 4, 2005

Opportunities

The BoxX-NoAF trial represents a massive opportunity to expand the surgical ablation market prophylactically to millions of cardiac surgery patients without prior Afib.

Furthermore, the Cryo Nerve Block platform has significant runway for growth by expanding into new surgical verticals like abdominal and orthopedic surgery, addressing the global imperative for non-opioid pain solutions.

Risk Factors

Key risks include regulatory and clinical trial setbacks (e.g., for BoxX-NoAF), reimbursement challenges for new technologies, and intense competition from larger, well-capitalized medical device giants in both the cardiac and pain management spaces.

Competitive Landscape

AtriCure competes with Medtronic and J&J in surgical ablation, holds a dominant leadership position over Abbott in surgical LAA management with AtriClip, and faces fragmented competition in the emerging cryoanalgesia space. Its integrated 'one-stop-shop' portfolio for the cardiac surgical suite provides a distinct competitive advantage.